Jupiter Topco LLC Makes New $754,000 Investment in Celcuity, Inc. $CELC

Jupiter Topco LLC acquired a new position in Celcuity, Inc. (NASDAQ:CELC) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 7,200 shares of the company’s stock, valued at approximately $754,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Legal & General Group Plc bought a new stake in shares of Celcuity during the 2nd quarter valued at about $1,763,000. The Manufacturers Life Insurance Company bought a new stake in Celcuity in the second quarter worth approximately $2,927,000. Brandywine Managers LLC bought a new stake in Celcuity in the second quarter worth approximately $693,000. Nan Fung Group Holdings Ltd acquired a new position in Celcuity in the second quarter valued at approximately $2,960,746. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new position in Celcuity in the second quarter valued at approximately $9,567,000. 63.33% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have recently commented on the stock. Stifel Nicolaus reduced their price objective on shares of Celcuity from $175.00 to $150.00 and set a “buy” rating for the company in a research report on Friday, August 14th. Needham & Company LLC dropped their target price on shares of Celcuity from $157.00 to $140.00 and set a “buy” rating on the stock in a research report on Friday, August 14th. Wells Fargo & Company cut their target price on shares of Celcuity from $183.00 to $166.00 and set an “overweight” rating on the stock in a research note on Wednesday, June 3rd. Craig Hallum restated a “buy” rating and issued a $178.00 price target on shares of Celcuity in a report on Wednesday, July 15th. Finally, Citizens Jmp reaffirmed a “market outperform” rating and issued a $177.00 price target on shares of Celcuity in a research note on Monday, August 17th. Ten equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $154.55.

Celcuity Stock Performance

Shares of Celcuity stock opened at $95.70 on Monday. The company has a debt-to-equity ratio of 6.04, a quick ratio of 8.93 and a current ratio of 8.93. Celcuity, Inc. has a 52 week low of $44.42 and a 52 week high of $151.02. The stock has a 50 day moving average price of $94.58 and a two-hundred day moving average price of $106.78. The stock has a market capitalization of $4.68 billion, a PE ratio of -22.26 and a beta of 0.19.

Celcuity (NASDAQ:CELC) last released its quarterly earnings data on Thursday, August 13th. The company reported ($1.44) EPS for the quarter, missing the consensus estimate of ($1.16) by ($0.28). As a group, equities analysts anticipate that Celcuity, Inc. will post -4.75 earnings per share for the current fiscal year.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.